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Osteoporosis in thalassaemia major (TM) represents a prominent cause of morbidity. The mechanism of pathogenesis of bone
disease(BD)inTMismultifactorialandcomplicated.Peakbonemassisachievedshortlyaftercompletionofpubertyandnormally
remains stable until the third decade of life when age-related bone mass begins. Growth hormone (GH) and sex steroids play a
crucial role in bone remodeling and in the maintenance of skeletal architecture during adult life. GH and insulin growth factors
(IGFs) have anabolic eﬀect in bone formation. Sex steroids act probably by increasing the expression of RANKL by osteoblastic
cells and alterations in the RANK/RANKL/OPG system in favor of osteoclasts. Impaired GH secretion and lack of sex steroids
in thalassemic patients due to pituitary damage, contribute to failure of achieving optimal peak bone mass. Other endocrine
complications such as hypoparathyroidism and vitamin D deﬁciency have also a detrimental role on bones in TM. It is still
questionable whether the international criteria for deﬁning osteopenia and osteoporosis are relevant to patients with TM; also a
question arises for the diagnostic methods such as DEXA scan and management of osteoporosis with known treatment protocols,
in the thalassaemic patient.
1.Introduction
Osteoporosis is a universal medical problem, aﬀecting both
genders. It is generally accepted that its main causes are
aging, genetic disorders of osteogenesis, lack of certain
nutritional elements or physical activity, and endocrine
disorders mainly estrogen deﬁciency. Other causes include
neoplastic disorders, gastrointestinal disorders causing mal-
absorption, liver diseases, inﬂammatory conditions, and
drugs. Osteopenia and osteoporosis represent prominent
causes of morbidity in patients of both genders with
thalassaemia [1]. During the last decade, the presence of
osteopenia and osteoporosis in well-treated thalassaemics
has been described in diﬀerent studies with high prevalence
up to 50% [2]. The pathogenesis of osteoporosis in tha-
lassaemia major (TM) is complicated and diﬀers from the
pathogenesis of bone deformities characteristically found in
nontransfused patients who develop bone distortion mainly
due to ineﬀective haemopoiesis and progressive marrow
expansion [3].
Several factors are implicated in reduction of bone mass
in TM. Delayed sexual maturation, growth hormone (GH)
and insulin growth factor-(IGF)-1 deﬁciency, parathyroid
gland dysfunction, diabetes, hypothyroidism, ineﬀective
haemopoiesis with progressive marrow expansion, direct
iron toxicity on osteoblasts, as well as liver disease have been
indicated as possible etiological factors for thalassaemia-
induced osteoporosis [2, 3]. Furthermore, iron chelation
has correlated with growth failure and bone abnormalities,
and high desferrioxamine dosage has been associated with
cartilage alterations [2, 4, 5].
2. The Role of RANK/RANKL/OPG System
Two distinct cell types are involved in the maintenance
and renewal of bone: (A) osteoblasts—cells of mesenchymal
lineage responsible for bone formation and (B) osteoclasts—
cells of hematopoietic lineage responsible for bone resorp-
tion and remodeling. In thalassemia patients, progressive
“aging” of the bone starts even in childhood by the
gradual development of an imbalance between augmented
osteoclastic resorption and insuﬃcient osteoblastic bone
formation.2 Journal of Osteoporosis
The bone marrow stromal cell molecules which are
members of the tumor necrosis factor (TNF) receptor
superfamily, receptor activator of nuclear factor-kappa B
ligand (RANKL), receptor activator of nuclear factor-kappa
B (RANK), and osteoprotegerin (OPG), play a central
role in bone remodeling via conjunction with various
cytokines and calciotropic hormones [6]. GH and IGF-1
stimulate the production of OPG and its accumulation in
the bone matrix. Sex steroids act probably by increasing the
expression of RANKL by osteoblastic cells [6]. Alterations
in the RANK/RANKL/OPG system in favor of osteoclasts
are characteristic in thalassaemia due to complicated mecha-
nisms involving chronic anemia, iron toxicity, and endocrine
complications.
In patients with Thalassaemia, elevated markers of bone
resorption such as serum alkaline phosphatase, osteocalcin,
urinary levels of N-telopeptides of collagen type I (NTX),
serum levels of tartrate resistant acid phosphatase isoform
5b (TRACP-5b), pyridinoline, and deoxypyridinoline are
found. Such elevated markers reveal increased osteoclastic
activity and enhanced osteoblastic dysfunction [7–12].
Several studies have recently proven that the ratio of
sRANKL/OPG is increased in patients with TM and low
bonemineraldensity(BMD),providingevidencefortherole
of RANKL/OPG system in the pathogenesis of osteoporosis
in thalassaemia. The increase of RANKL, followed by
unmodiﬁed OPG levels, with the consequent increase of
RANKL/OPGratiomayrepresentthecauseofuncouplingon
bone turnover observed in thalassaemia patients [2, 9, 12].
A negative correlation between the sRANKL/OPG ratio and
free testosterone in male thalassaemia patients and between
17-b oestradiol in female thalassaemia, which has also been
proven, speculates the role of RANKL/OPG system on the
action of sex steroids on bone [12].
3. Hypogonadotrophic Hypogonadism
It is well known that sex steroids regulate skeletal maturation
and preservation in both men and women. The impact of
gonadal insuﬃciency on skeletal integrity has been widely
recognized in adult men and women ever since. Androgens
can be converted into estrogens within the gonads and
peripheral tissues and both are present in men and women.
S e xs t e r o i ds i g n a l i n gv i as e xs t e r o i dr e c e p t o r sf o u n di nb o n e
possibly aﬀects bone formation and preservation. The exact
role of steroids in the pathogenesis of osteopenia is not
completely clear. However, it is suggested that sex steroids
may act by altering the normal balance of the OPG/RANKL
system. Sex steroids increase the expression of RANKL by
osteoblastic cells [12]. Oestrogen and progesterone appear to
inhibit osteoclastic activity and promote osteoblastic activity
[13] while testosterone has a direct stimulatory eﬀect on
osteoblast proliferation and diﬀerentiation [14]. Thus in the
lack of steroids, the osteoclastic activity increases resulting in
osteopenia.
Association between hypogonadotrophic hypogonadism
andosteoporosisinadultpatientswithTMhasbeenreported
in the past [15, 16]. The contribution of sex steroids in
addition to other factors on the development of bone
disease in TM has been unequivocally proven [2, 17, 18].
Iron deposition on gonadotrophic cells leads to disruption
of gonadotrophin production and consequently leads to
delayed puberty and hypogonadotrophic hypogonadism.
More than 50% of TM females fail to attend menarche
and present with Primary Amenorrhea while Secondary
Amenorrhea will invariably develop with time especially
in patients poorly compliant to chelation therapy [19–21].
Male patients develop hypogonadotrophic hypogonadism
and secondary gonadal failure resulting in low testosterone
secretion [22, 23]. Primary gonadal failure may also present
due to iron deposition on the testes and ovaries [23, 24].
Patients carrying certain genetic defects have an in-
creased degree and rate of iron overloading through transfu-
sions over the years and their Ferritin levels poorly correlate
with their total body iron concentrations as proven by
the increased frequency of hypogonadism. The role of the
genotype as an independent risk factor for the development
of endocrine complications in patients with TM on chelation
therapy can be explained by the diﬀerences in the actual
and realistic haemosiderosis, because the patients with the
more severe defects have a greater rate of iron loading
through higher red cell consumption. [15]. This observation
is further supported by the ﬁnding of our previous study,
which showed that gonadal function was the only factor
strongly associated with decreased BMD when the patients
were grouped based on genotype [16].
Throughout childhood, BMD normally rises at a steady
rate until the age of about 12 years and then there is a sudden
acceleration of bone mineral accretion, which coincides with
the onset of puberty and the pubertal growth spurt. In
patients with thalassaemia, BMD which is already low in
childhood [25] decreases further during and after puberty
especially in patients with absent or delayed puberty [26].
Bielinski et al. have proved that thalassemic adolescents who
failed to progress normally through puberty also failed to
preserve adequate bone mineralization and achievement of
peak bone mass [27]. Other studies have shown subopti-
m a lb o n ea c c r u a l ,r e g a r d l e s sn o r m a lo ri n d u c e dp u b e r t y
[1, 28, 29].
R e d u c e db o n em a s si sd e ﬁ n i t e l ym o r ec o m m o na m o n g
adultpatientswithTMduetohypogonadismwhichhasbeen
proposed as a mechanism for osteopenia on this condition.
In adult TM patients, the prevalence of osteoporosis and
osteopenia is above 50%, and vertebral fractures have been
reported in up to 20% of patients [8]. However many
otherfactorsincludingtheseverityofthehemoglobinopathy,
concomitant treatments, and gender diﬀerences in bone
mass acquisition and maintenance are implicated in bone
metabolism in hypogonadal thalassemics. Regarding the
hormonal replacement therapy (HRT), there is conﬂicting
evidence on its clinical eﬀectiveness in maximizing bone
mass in TM patients. Some studies have shown beneﬁcial
eﬀect of HRT especially in younger patients [8, 11] while
someothershaveshownlittleornoeﬀectofHRTonBMDin
thalassaemics who presumably have not achieved peak bone
mass [30].Journal of Osteoporosis 3
4.GH-IGFAxis
Although sex steroids are essential for the preservation of
BMD during adolescence and adulthood, insulin growth
factors (IGFs) and GH play a crucial role on bone formation
during childhood and bone maintenance later in life. A
number of clinical studies have provided evidence for
potential eﬀect of GH/IGF system on bone mass. However,
our understanding of the regulation of production and
actions of GH/IGF system on bone is incomplete. The
anabolic eﬀects of GH and IGF-1 in bone are important for
theacquisitionofbonemassduringadolescenceandpossibly
for the maintenance of skeletal architecture during adult life.
The changes in GH and IGF-I secretion that occur with
aging are paralleled by a progressive loss of muscle mass and
strength, a decline in physical performance, an increase in
body fat, and a decrease in BMD [31]. The skeletal eﬀects of
GHand IGFare modulated by complexinteractions between
circulatingIGF-IandIGF-bindingproteins(IGFBPs)andthe
locally produced IGF-1 and IGFBPs.
Growth hormone stimulates the proliferation of cells of
the osteoblastic lineage [32] although IGF-1 is required for
selected anabolic eﬀects of GH in osteoblasts [33]. Speciﬁ-
cally, GH aﬀects the fate of mesenchymal precursors favoring
osteoblastogenesis and chondrogenesis and opposing adi-
pogenesis [33]. In addition, it stimulates the expression of
bone morphogenetic proteins, which are important for the
diﬀerentiation of osteoblasts, bone formation [34] and the
production of OPG and its accumulation in the bone matrix
[35]. Via these mechanisms, GH stimulates longitudinal
bone growth, either directly or through an eﬀect mediated
by the local IGF-1 [35].
The fundamental role of IGF-1 is the stimulation of
osteoblastic function and bone formation. IGF-1 has modest
eﬀects on the proliferation of cells of the osteoblastic
lineage and enhances the function of the mature osteoblast
[36]. Additionally, IGF-1 upregulates collagen synthesis and
decreases its degradation, which is important for maintain-
ing the appropriate levels of bone matrix and bone mass.
Less clear is the function of IGF-1 on osteoclasts. Osteoclasts
e x p r e s sI G F - 1r e c e p t o r sa n dI G F - 1h a sd i r e c te ﬀects on their
function [37].
Impaired GH secretion is not a rare occurrence in
adult thalassaemics, which contributes to osteopenia and
osteoporosis. However, as it was proven in the past the
majorityofTMpatientshavethesameGHsecretionasinthe
normal population [38]. Some studies have shown impaired
GH response to GH-challenge tests in TM patients aged 10–
23 years [39, 40]. Others have reported 3.1% of thalassemics
to have GHRH-GH-IGF-1 axis dysfunction [41], which is
attributed to multiple mechanisms such as neurosecretory
dysfunction, hypothalamic GH-releasing hormone (GHRH)
deﬁciency, and increased somatostatin activity [42, 43].
Additionally, thalassemic patients with delayed puberty do
not exhibit normal growth spurt; their GH peak amplitude
is reduced as well as their nocturnal GH levels [42, 44].
Thalassemics are also proven to have low IGF-1 levels in high
prevalence regardless normal or subnormal GH secretion
[45]. Recently, it has been reported that defective GH
secretion and diminished serum IGF-1 levels may contribute
tofemoraldemineralization inTMpatients [45].Inthefavor
of further investigation, it is valuable that GH status should
be retested in thalassaemic patients with childhood onset
of GHD [46]. If the diagnosis of adult GHD is established,
GH treatment is worth considering as it could contribute to
i m p r o v eb o n em i n e r a ld e n s i t y .
There are no data of GH treatment in adults with
thalassaemia and how this treatment may contribute to the
improvementofBMDofthesepatients.InastudyofSartorio
et al., one year of GH treatment in thalassemic children is
able to increase, but not normalize, bone turnover; however
it is insuﬃcient to improve BMD values [47]. Prolonged
periods of GH therapy are probably requested to positively
aﬀect both bone turnover and BMD values in GH deﬁcient
thalassaemic patients, as it occurs in children and adults with
GH deﬁciency.
5. HypoparathyroidismandVitaminD
Deﬁciency
Hypoparathyroidism is another endocrine complication in
thalassaemia, which may develop in late adolescence and
contribute to osteopenia and subsequently osteoporosis. A
recent study has reported prevalence up to 13.5% with
no sex diﬀerences [48]. Iron overload with deposition on
parathyroid cells and tissue ﬁbrosis are the main causes
of hypoparathyroidism while chronic anemia is an addi-
tional factor causing parathyroid dysfunction [49]. The
condition presents with the typical biochemical picture of
hypoparathyroidism of low calcium and high phosphate
levels. PTH may be normal or low and vitamin D is low.
Low calcium and phosphorus are found in 24-hour urine
collection. Bone X-rays are characteristic for osteoporosis.
Abnormal cerebral CT ﬁndings are reported to be related
with hypoparathyroidism in thalassemics [48, 49].
Vitamin D deﬁciency may start early in thalassemics,
before hypoparathyroidism is established. Vitamin D deﬁ-
ciency potentially contributes to low bone mass in tha-
lassaemia. Notably, TM patients progressively develop iron
overload, and it is possible that a deﬁciency in liver hydrox-
ylation of vitamin D, or in vitamin D absorption, appears
in older thalassemic patients. However, studies in children
[50, 51] and in adult thalassemic patients [52, 53]h a v e
shown contradictory results. Voskaridou et al. evaluating
45 adult TM patients reported that serum vitamin D (25-
OH and 1,25-OH-vitamin D) levels were within normal
limits in almost all patients [8]. Conversely, Pratic` oe ta l .
[53] observed that 32 of 113 thalassemic patients (including
children and adults) had low serum levels of 25-OH-
vitamin D. Other studies have proved a disturbance in the
circulating levels of 25-OHD in thalassaemic patients which
isaggravatedwithincreasingage[54].Itisdiﬃculttoexplain
these diﬀerences due to the multiple factors implicated in
the mechanism of vitamin D deﬁciency. Additionally in
countries with poor sunlight, vitamin D deﬁciency is more
common even in the normal population. It is, though,4 Journal of Osteoporosis
importanttoconsidersolarirradiationasavitalfactortaking
action in the metabolism of vitamin D.
Inaddition to vitamin D, vitamin C and trace elements
suchaszincandcooperareinvolvedinthebonemetabolism.
Vitamin and trace mineral deposition is proven to be inhib-
ited by desferrioxamine in thalassemic patients who receive
inappropriately high doses of this chelating agent. Mineral
depletion may result in decrease of alkaline phosphatase
activity, a zinc-dependant enzyme. Direct toxicity of desfer-
rioxamine by inhibiting cell proliferation, DNA synthesis,
and collagen formation cause bone damage resulting in
platyspondylosis with ﬂattening of the vertebral bodies and
consequently shortening of the spinal height [5].
On the other hand iron deposition in bone may
impairosteoidmaturationandinhibitmineralizationlocally,
resulting in focal osteomalacia. Iron interferes in osteoid
maturation and mineralization by the incorporation into
crystalsofcalciumhydroxyapatitewhichconsequentlyaﬀects
the growth of calcium hydroxyapatite crystals and increases
osteoid in bone tissue [28]. A damaged bone with small size
may simply contribute to the markedly low BMD seen in the
thalassemic patients.
6. Gender Differences in Bone Disease in TM
The impact of gonadal insuﬃciency on skeletal integrity has
been widely recognized in both genders. It is though unclear
whether there are gender diﬀerences in bone disease in TM.
Some studies support that there is a gender diﬀerence not
only in the prevalence but also in the severity of osteoporosis
syndrome in TM. A recent study by our institution showed
that male patients were more frequently and more severely
osteopenic/osteoporotic than females (Figure 1)[ 55]. Other
studies also showed male predominance on osteoporosis
although some other reported no gender variation [56–60].
On the other hand, primary amenorrhea and, furthermore,
hypogonadism are proven to have a greater impact on
osteoporosis in females rather than in males [56]. Addition-
ally, eugonadal females are less severely aﬀected, on spine,
compared with eugonadal males most likely due to the
beneﬁcial eﬀect of HRT in women with TM (Figure 2)[ 55].
Alternatively, the bones of male patients are more vulnerable
to the adverse eﬀect of other contributing factors, which
operate with a complicated and still unknown mechanism.
However, some studies showed no gender diﬀerences in
hypogonadal patients with TM [59, 60].
7.DiagnosticMethods ofOsteoporosis
Syndrome in TM
BMD is generally measured by the Dual Energy X-ray
Absorption (DEXA) method. However, it is known that TM
patients have spinal degenerative skeletal changes, which can
be detected only by MRI and more likely interfere with BMD
values, resulting in false diagnosis of bone disease (BD).
Therefore, DEXA scans may fail to provide accurate and
preciseinformationonosteoporosisinthalassaemicpatients.
This probably explains the discrepancy between the ﬁndings
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Figure 1: Prevalence (%) of osteoporosis osteopenia syndrome in
hypogonadal male and female patients with TM.
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Figure 2: Mean BMD (spine) values in non-hypogonadal male and
female patients with TM.
of osteoporosis in TM in diﬀerent studies. For example in a
recent Iranian study by Shamshirsaz et al. the prevalence
of osteoporosis was found in 44% of the patients by using
the DEXA method whereas only 6% of the same population
were osteoporotic based on the Quantitative Computed
Tomography (QCT) [59].
One additional contributing factor that interferes with
BMD readings in DEXA method is short stature of tha-
lassaemia patients, attributed mostly in the shortening of
the spine. The reason is that DEXA measurements are
inﬂuenced by size and that BMD represents a measurement
of bone area rather than volume, leading to underestimation
of bone density in such individuals. In summary, since
DEXA may fail to provide accurate information of BD in
thalassaemia, other methods, such as QCT, high resolution
computed tomography and single energy quantitative com-
p u t e dT o p o g r a p h y( S E Q C T )s h o u l db ec o n s i d e r e da sb e i n g
more sensitive and reliable to detect bone disease in this
condition.Journal of Osteoporosis 5
8. GeneralAspects in Management of
Osteoporosis in TM
The gold key in the management of osteoporosis in patients
with TM, in whom, loss of bone mass starts early, is
prevention. Treatment of anemia with regular transfusions
and the management of iron overload with prompt chelation
are mandatory for every patient with thalassaemia in order
to avoid adverse events of the disease on bones. Additional
lifestyle measures should be encouraged such as physical
activity and smoking quitting. Adequate calcium and vita-
min D intake during skeletal development can increase
bone mass in adult life with the ﬁnal goal to prevent bone
loss and fractures. Early recognition and management of
endocrine complications of thalassaemia are essential for
eliminating the risk of BD. Induction of puberty at a proper
age and treatment of hypogonadism with HRT seem to
be the most eﬀective ways for preventing osteoporosis and
other bone deformities in thalassaemia [17]. Calcitonin,
a potent inhibitor of osteoclasts, has also been tried in
combination with calcium and vitamin D [60]. Bisphospho-
nates are worldwide used in patients with postmenopausal
osteoporosis to increase BMD and prevent bone fractures
[61]. The reduction in fractures may be related not only
to the increase in bone mass arising from the inhibition of
bone resorption and reduced activation frequency of bone-
remodeling units but also to enhanced osteomineralization.
Alendronate, pamidronate, and zoledronic acid seem to have
greater eﬃcacy in osteoporotic patients with TM either with
normal or impaired gonadal function [8, 9, 62, 63]. Since the
originofbonediseaseinTMismultifactorialandsomeofthe
underlying pathogenic mechanisms are still unclear, further
research in the therapeutic trials with bisphosphonates is
needed to allow deﬁnite conclusions.
9. Conclusion
It is obvious that osteoporosis in thalassemia is of multi-
factorial etiology and of complex mechanism which need
to be clariﬁed. Endocrine complications mentioned in this
paper inaddition to progressive marrow expansion, iron and
desferrioxamine toxicity on bones, as well as liver disease
contribute to the complex mechanism of osteoporosis in
thalassaemia patients. Thus, osteoporosis in TM represents
a unique clinical entity, which adversely aﬀects the life
expectancy of patients with TM. It is still questionable
whether the international criteria for deﬁning osteopenia
and osteoporosis are relevant to patients with TM; also a
question arises for the diagnostic methods and management
of osteoporosis in the thalassaemic patient as multiple
factors are involved in its pathogenesis. Close follow-up early
recognition of osteopenia, as well as proper management are
crucial for every thalassemic patient giving him the right to
live a better life.
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